Department of Health Services Research, Faculty of Health, Medicine and Life Sciences, CAPHRI, Maastricht University Medical Center, Maastricht University, Universiteitssingel 60, 6229, Maastricht, The Netherlands.
Department of Economics and Finance, Faculty of Economics and Finance, University of Rome Tor Vergata, Via Columbia 2, 00133, Rome, Italy.
Eur J Health Econ. 2022 Mar;23(2):177-192. doi: 10.1007/s10198-021-01358-1. Epub 2021 Aug 4.
Obesity is a complex health disorder that significantly increases the risk of several chronic diseases, and it has been associated with a 5-20-year decrease in life expectancy. The prevalence of obesity is increasing steadily worldwide and Italy follows this trend with an increase of almost 30% in the adult obese population in the last 3 decades. Previous studies estimated that 2-4% of the total health expenditure in Europe is attributed to obesity and it is projected to double by 2050. Currently, there is a lack of sufficient knowledge on the burden of obesity in Italy and most relevant estimates are derived from international studies. The aim of this study is to estimate the direct and indirect costs of obesity in Italy, taking 2020 as the reference year.
Based on data collected from the literature, a quantitative cost-of-illness (COI) study was performed from a societal perspective focussing on the adult obese population (Body Mass Index (BMI) ≥ 30 kg/m) in Italy.
The study indicated that the total costs attributable to obesity in Italy amounted to €13.34 billion in 2020 (95% credible interval: €8.99 billion < µ < €17.80 billion). Direct costs were €7.89 billion, with cardiovascular diseases (CVDs) having the highest impact on costs (€6.66 billion), followed by diabetes (€0.65 billion), cancer (€0.33 billion), and bariatric surgery (€0.24 billion). Indirect costs amounted to €5.45 billion, with almost equal contribution of absenteeism (€2.62 billion) and presenteeism (€2.83 billion).
Obesity is associated with high direct and indirect costs, and cost-effective prevention programmes are deemed fundamental to contain this public health threat in Italy.
肥胖是一种复杂的健康紊乱,会显著增加多种慢性疾病的风险,并且与预期寿命缩短 5-20 年有关。全球肥胖患病率稳步上升,意大利也紧随这一趋势,在过去 30 年中,成年人肥胖人口增加了近 30%。先前的研究估计,欧洲总医疗支出的 2-4%归因于肥胖,预计到 2050 年将翻一番。目前,意大利对肥胖负担的了解还不够充分,大多数相关估计都来自国际研究。本研究旨在估计 2020 年意大利肥胖的直接和间接成本。
本研究从社会角度出发,基于文献中收集的数据,对意大利成年肥胖人群(BMI≥30kg/m)进行了一项定量疾病成本(COI)研究。
该研究表明,2020 年意大利肥胖相关总成本为 133.4 亿欧元(95%可信区间:89.9 亿欧元<µ<178 亿欧元)。直接成本为 78.9 亿欧元,其中心血管疾病(CVDs)对成本的影响最大(66.6 亿欧元),其次是糖尿病(6.5 亿欧元)、癌症(3.3 亿欧元)和减重手术(2.4 亿欧元)。间接成本为 54.5 亿欧元,其中旷工(26.2 亿欧元)和出勤(28.3 亿欧元)的贡献几乎相等。
肥胖与高直接和间接成本相关,因此,实施具有成本效益的预防计划对于遏制意大利的这一公共卫生威胁至关重要。